The N-MOmentum trial: Building momentum to advance trial methodology in a rare disease

Abstract

Get full access to this article

View all access options for this article.

References

Orphan Medicinal Product Regulation. Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products (Official Journal 2000; L18:15), http://ec.europa.eu/health/files/eudralex/vol-1/reg_2000_141/reg_2000_141_en.pdf

Gagne

Thompson

O’Keefe

. Innovative research methods for studying treatments for rare diseases: Methodological review. BMJ 2014; 349: g6802.

Unkle

Rover

Stallard

. Systematic reviews in paediatric multiple sclerosis and Creutzfeldt-Jakob disease exemplify shortcomings in methods used to evaluate therapies in rare conditions. Orphanet J Rare Dis 2016; 11: 16.

Cree

Sheehan

Cohen

. A placebo-controlled study in neuromyelitis optica-ethical and design considerations. Mult Scler. Epub ahead of print 14 December 2015. DOI: 10.1177/1352458515620934.

Kleiter

Gahlen

Borisow

. Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol 2016; 79: 206–216.

Weinshenker

BG.

Placebo studies should not be undertaken in Neuromyelitis Optica: Commentary. Mult Scler 2015; 21: 693–694.

Gross

Friede

Hilgers

. Safety and efficacy of the ACE-inhibitor ramipril in Alport syndrome: The double-blind, randomized, placebo-controlled, multicenter phase III EARLY PRO-TECT Alport trial in pediatric patients. Pediatrics 2012; 2012: 436046.

Chataway

Nicholas

Todd

. A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis. Mult Scler 2011; 17: 81–88.

Nicholas

Straube

Schmidli

. Trends in annualized relapse rates in relapsing-remitting multiple sclerosis and consequences for clinical trial design. Mult Scler 2011; 17: 1211–1217.

10.

Friede

Röver

Wandel

. Meta-analysis of few small studies in orphan diseases. Res Synth Method, in press.

11.

Baeten

Baraliakos

Braun

. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: A randomised, double-blind, placebo-controlled trial. Lancet 2013; 382: 1705–1713.